Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
This is an open labeled, one-armed real-world study in Irritable Bowel Syndrome (IBS)-patients. All participants will receive active treatment for 12 weeks. Patients received daily orally administrated 5-g intervention of the HMOs 2’-fucosyllactose and lacto-Nneotetraose in a 4:1 mix.
Primary outcome measures:
Change from baseline in bowel function
The authors' conclusion was: Supplementation with 2 selected HMOs improves IBS symptoms and quality of life without substantial side effects. These promising results suggest that this novel approach to IBS should be confirmed in a randomized, placebo-controlled trial.
…